Tag Archives: AST

H.C. Wainwright Sticks to Its Buy Rating for Asterias Biotherapeutics (AST)

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Asterias Biotherapeutics (NYSE: AST) today and set a price target of $11. The company’s shares closed yesterday at $1.40, close to its 52-week low of $1.20. According to TipRanks.com, Selvaraju

Analysts Are Bullish on Top Healthcare Stocks: Asterias Biotherapeutics (AST), Cyclacel Pharmaceuticals (CYCC)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Asterias Biotherapeutics (NYSE:AST) and Cyclacel Pharmaceuticals (NASDAQ:CYCC) with bullish sentiments. Asterias Biotherapeutics (AST) In a report released today, Ram Selvaraju from H.C.

Asterias Biotherapeutics (AST) Receives a Buy from H.C. Wainwright

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Asterias Biotherapeutics (NYSE: AST) today and set a price target of $11. The company’s shares closed yesterday at $1.55, close to its 52-week low of $1.20. Selvaraju wrote: “Valuation methodology,

B.Riley FBR Maintains a Buy Rating on Asterias Biotherapeutics

B.Riley FBR analyst George Zavoico maintained a Buy rating on Asterias Biotherapeutics (NYSE: AST) today and set a price target of $6. The company’s shares opened today at $1.75. Zavoico noted: “Asterias Biotherapeutics, Inc. (AST) announced additional interim results of

Asterias Biotherapeutics Receives a New Rating from H.C. Wainwright

Asterias Biotherapeutics (NYSE: AST) received a Buy rating and a $11 price target from H.C. Wainwright analyst Ram Selvaraju today. The company’s shares closed yesterday at $1.85. Selvaraju observed: “We reiterate our Buy rating and 12-month price target of $11

B.Riley FBR Thinks Asterias Biotherapeutics’ Stock is Going to Recover

Asterias Biotherapeutics (NYSE: AST) received a Buy rating from B.Riley FBR analyst George Zavoico today. The company’s shares closed yesterday at $2.05, close to its 52-week low of $1.95. Zavoico noted: “We are initiating coverage of Asterias Biotherapeutics, Inc. (AST)